Skip to main content

Table 1 Baseline characteristics of the patients

From: Hyperlactatemia is a predictor of mortality in patients undergoing continuous renal replacement therapy for acute kidney injury

  

Lactate groups

 

Variables

All

(n = 1,661)

Low

(n = 317)

Moderate

(n = 802)

High

(n = 542)

P

Age (years)

63.6 ± 15.1

64.1 ± 15.8

64.2 ± 15.2

62.7 ± 14.7

0.144

Female (%)

37.8

36.0

35.0

41.4

0.041

Weight (kg)

65.3 ± 13.0

62.3 ± 13.7

62.2 ± 12.6

62.4 ± 13.1

0.542

Septic acute kidney injury (%)

58.6

54.6

55.8

63.3†

0.005

Target dose (ml/kg/hr)

41.0 ± 12.8

39.8 ± 12.9

39.8 ± 12.4

42.8 ± 13.4†

 < 0.001

Blood flow rate (ml/min)

113.4 ± 24.8

114.1 ± 25.3

112.7 ± 24.0

113.6 ± 25.3

0.674

Target ultrafiltration (ml/d)

0 (–500–0)

0 (–500–0)

0 (–500–0)

0 (–500–0)

0.761

Mechanical ventilation (%)

77.2

62.8

76.2‡

84.9‡

 < 0.001

Use of ≥ 3 vasopressors (%)

17.5

6.6

13.9†

26.0‡

 < 0.001

ICU type (%)

    

0.110

 Medical ICU

60.9

58.7

61.1

61.7

 

 Surgical ICU

18.8

21.8

17.7

18.6

 

Cardiopulmonary ICU

1.5

2.2

2.1

0.6

 

 Emergency ICU

18.5

16.7

18.9

19.1

 

 COVID-19 ICU

0.2

0.6

0.3

0.0

 

SOFA score

12.0 ± 3.7

9.9 ± 3.4

11.8 ± 3.6‡

13.1 ± 3.5‡

 < 0.001

APACHE II score

26.5 ± 7.8

23.1 ± 7.3

26.1 ± 7.7‡

28.6 ± 7.6‡

 < 0.001

CCI score

2 (1–3)

2 (1–3)

2 (1–3)

2 (1–3)

0.868

  1. ICU intensive care unit, COVID-19 COrona VIrus Disease-19, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation, CCI Charlson comorbidity index
  2. *P < 0.05; †P < 0.01; ‡P < 0.001 compared with the low lactate group